Ensifentrine

New data from the Phase 3 ENHANCE trials demonstrates that ensifentrine, a dual phosphodiesterase 3 and 4 inhibitor, significantly improves lung function and reduces exacerbations in COPD patients.

Vivo Capital has closed the third cycle of its Opportunity Fund with over $740 million in commitments, focusing on preclinical and clinical-stage life sciences companies developing novel therapies.

Verona Pharma will present ten posters at ATS 2025, including seven analyses from Phase 3 ENHANCE studies demonstrating Ohtuvayre's efficacy in diverse COPD patient populations.

Ohtuvayre (ensifentrine), a first-in-class dual PDE3/PDE4 inhibitor, has received regulatory approval in Macau SAR for maintenance treatment of COPD in adult patients.

Verona Pharma's ensifentrine significantly reduced COPD exacerbations by 42% in the ENHANCE-2 phase 3 trial, paving the way for regulatory filings.